- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01705197
This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction. (SPEED)
A Double-blind, Stratified Randomization, Placebo Controlled, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Avanafil in Subjects With Moderate to Severe Erectile Dysfunction in Korea.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Catholic Univ. Seoul St. Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients over 20 years old with a history of erectile dysfunction for at least 6 months prior to participation in the study
- Patients in a stable relationship with 1 female partner
- Patients whose sex partner is not in pregnancy or lactating, and is taking proper contraceptive
- Patients who have voluntarily decided to participate in this clinical trial, and signed the informed consent form
- Patients whose failure rate for sexual intercourse is more than 50% after attempts of sexual intercourse on more than 3 different days (once/day) at least during the 4-week Free run-in period
- Patients whose EF domain score is less than 18 points (moderate to severe erectile dysfunction) in the IIEF questionnaire after the 4-week Free run-in period
Exclusion Criteria:
- Patients who have a spinal injury or have had a radical prostatectomy
- Patients with anatomical malformations of the penis (example: angulation, fibrosis of corpus cavernosum, peyronies disease, etc.)
- Patients who had surgery in the pelvic cavity within 6 months prior to participation in the study
Patients with neurogenic or endocrine (example: hyperprolactinemia, low testosterone, etc.) ED
- Hyperprolactinemia: Serum prolactin ≥ 3 X ULN
- Low testosterone: Total testosterone is less than the normal lower limit(testosterone is susceptible to daily changes, so enrollment is permitted after retesting before 11 am, only limited to once, when the number is 20% less than the normal lower limit.)
- Patients with a major refractory psychiatric disorder (including major depression or schizophrenia) or significant neurological abnormalities (neurovascular disease)
- Patients with alcohol addiction or persistent abuse of drugs of dependence
Patients with hepatic dysfunction or renal dysfunction as per the following:
- Hepatic dysfunction: AST, ALT ≥ 3 X ULN
- Renal dysfunction: Serum creatinine > 2.0mg/dL
- Diabetic patients whose HbA1c exceeds 12%
- Patients with proliferative diabetic retinopathy
- Patients who have had a stroke, TIA(Transient ischemic attack), MI(Myocardial Infarction) or fatal arrhythmia, or severe heart failure, unstable angina or who underwent coronary artery bypass grafting (CABG) within the last 6 months prior to participation in the study
- Patients with hypotension (resting SBP/DBP in the sitting position is less than 90/50mmHg) or unregulated hypertension (resting SBP/DBP in the sitting position exceeds 170/100mmHg)
- Patients with hematopathy, which can be a predisposition to priapism (sickle-cell disease, multiple myeloma, leukemia)
- Patients with a known genetically degenerative retinopathy, including retinitis pigmentosa
- Patients who have had experience with avanafil, viagra, cialis, levitra, yaila, zydena, mvix or other ED treatment within 2 weeks from participation in the study
Patients administered with the following medications:
- Nitrate/Nitric oxide (NO) donors (example: nitroglycerin, isosorbide mononitrate, amyl nitrate/nitrite, sodium nitroprusside)
- Androgens (example: testosterone), anti-androgen, trazodone
- Anticoagulant (antiplatelet agents excluded)
- Agents that significantly affect the CYP450 3A4 intermediary metabolism, such as erythromycin, intraconazol, ketoconazol, cimetidine, ritonavir, saquinavir, amprenavir, indinavir, and nelfinavir, etc.
- Patients who have had a history of hypersensitivity to other PDE-5 inhibitors or who have not responded to them
- Patients with primary hyposexuality
- Patients who have taken other investigational products within 4 weeks before the study
- For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate due to clinically significant findings according to the medical decision of the principal investigator or the study personnel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Avanfil 100 or 200mg
All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization.
When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
|
This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study.
For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period.
For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1.
At this time, subjects are random stratified to each group depending on their diabetes status.
Other Names:
|
Placebo Comparator: Placebo 100mg or 200mg
When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
|
This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study.
For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period.
For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1.
At this time, subjects are random stratified to each group depending on their diabetes status.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare with the changes in IIEF(The International Index of Erectile Function)Erectile Function domain score between the study group and control group.
Time Frame: 12 weeks
|
When changes in IIEF EF domain score of the study group (Avanafil-administered group) and control group (placebo-administered group) are compared to the baseline after 12 weeks post medication, it is to evaluate the superiority of the study group.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare with the MSHQ, SEP Q2, SEP Q3 and GEAQ.
Time Frame: 12 weeks
|
[Glossary] MSHQ: Male Sexual Health Questionnaire SEP: Sexual Encounter Profile SEP Q2: Intercourse success rates on the Sexual Encounter Profile SEP Q3: Erectile success rates on the Sexual Encounter Profile GEAQ:Global Assessment Question |
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
We will be confirming the safety after initiating treatment with Avanafil 100mg and later increasing to 200mg, compared with continuing treatment with Avanafil 100mg.
Time Frame: 12weeks
|
|
12weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kim Se Woong, Doctor, Catholic hospital in Korea
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JW-AVA-302
- 임상제도과-2221 (Other Identifier: KFDA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Avanafil 100 or 200mg
-
VIVUS LLCCompletedAvanfil ADME | Semen Exposure | Sperm FunctionUnited States
-
VIVUS LLCCompleted
-
OrthoTrophix, IncCompleted
-
Juventas Therapeutics, Inc.CompletedCritical Limb IschemiaUnited States, India
-
SironRX Therapeutics, Inc.UnknownMedian SternotomyUnited States
-
National Taiwan University HospitalMrs. Hsiu-Chin Lee Kidney Research FundUnknown
-
Samyang Biopharmaceuticals CorporationSeoul National University HospitalCompletedHealthy, MaleKorea, Republic of
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingNon-Small Cell Lung Cancer、EGFR Sensitive MutationChina
-
The University of Texas Health Science Center at...RecruitingNeonatal Abstinence SyndromeUnited States